Literature DB >> 6194284

Interactions in the behavioral effects of methylxanthines and adenosine derivatives.

J J Katims, Z Annau, S H Snyder.   

Abstract

The role of adenosine receptors in behavioral effects of alkylxanthines was evaluated in mice. The relative potencies of alkylxanthines in reversing locomotor activity depression elicited by L-phenylisopropyladenosine (L-PIA) were similar to relative potencies in competing for adenosine receptors labeled by [3H]cyclohexyladenosine. Whereas L-PIA at i.p. doses of 0.10 mumol/kg and higher depressed locomotor activity, lower doses (0.01 and 0.05 mumol/kg) augmented locomotor activity. At the doses evaluated, caffeine did not further augment the L-PIA (0.05 mumol/kg)-enhanced locomotor activity. Low doses of diazepam, like L-PIA, augmented locomotor activity. Combining locomotor depressant doses of diazepam and caffeine produced a paradoxical stimulation of activity, as observed also for L-PIA and caffeine. Low doses of diazepam but not L-PIA increased crossings between the light and dark sites in a shuttle box, indicating a difference in the behavioral profile of these two agents. At behaviorally effective doses, L-PIA did not alter blood pressure or heart rate, but elicited some premature ventricular contractions which, however, occurred to a similar extent at locomotor depressant and stimulant doses of L-PIA. Brain levels of L-PIA at the lowest behaviorally active doses were adequate to occupy more than 50% of adenosine receptors. Thus, the behavioral effects of L-PIA appeared to be mediated in the brain and were not secondary to the cardiovascular effects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6194284

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  22 in total

Review 1.  Presynaptic modulation controlling neuronal excitability and epileptogenesis: role of kainate, adenosine and neuropeptide Y receptors.

Authors:  João O Malva; Ana P Silva; Rodrigo A Cunha
Journal:  Neurochem Res       Date:  2003-10       Impact factor: 3.996

2.  Inhibition of the shake response in rats by adenosine and 2-chloroadenosine.

Authors:  S Y Tse; E T Wei
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Activation of hippocampal adenosine A3 receptors produces a desensitization of A1 receptor-mediated responses in rat hippocampus.

Authors:  T V Dunwiddie; L Diao; H O Kim; J L Jiang; K A Jacobson
Journal:  J Neurosci       Date:  1997-01-15       Impact factor: 6.167

4.  The role of adenosine receptors in the central action of caffeine.

Authors:  John W Daly; Dan Shi; Olga Nikodijevic; Kenneth A Jacobson
Journal:  Pharmacopsychoecologia       Date:  1994

5.  The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors.

Authors:  M El Yacoubi; C Ledent; J F Ménard; M Parmentier; J Costentin; J M Vaugeois
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

Review 6.  Pharmacological rationale for the clinical use of caffeine.

Authors:  J Sawynok
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

7.  Behavioral effects of A1- and A2-selective adenosine agonists and antagonists: evidence for synergism and antagonism.

Authors:  O Nikodijević; R Sarges; J W Daly; K A Jacobson
Journal:  J Pharmacol Exp Ther       Date:  1991-10       Impact factor: 4.030

8.  Striatal A2 receptor regulates apomorphine-induced turning in rats with unilateral dopamine denervation.

Authors:  S J Brown; R Gill; J L Evenden; S D Iversen; P J Richardson
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

9.  Methylxanthine-induced attenuation of pecking in chickens.

Authors:  M R Zarrindast; T Nasir
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

10.  Psychomotor stimulant effects of methylxanthines in squirrel monkeys: relation to adenosine antagonism.

Authors:  R D Spealman
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.